402948-37-2

Basic information

• Product Name: Ethyl 2-[5-(4-methylpiperazinyl)benzimidazol-2-yl]acetate
• Synonyms: Ethyl 2-[5-(4-methylpiperazinyl)benzimidazol-2-yl]acetate;ethyl 2-(6-(4-Methylpiperazin-1-yl)-1H-benzo[d]iMidazol-2-yl)acetate;ethyl 2-(5-(4-Methylpiperazin-1-yl)-1H-benzo[d]iMidazol-2-yl)acetate;CHIR161527;ETHYL 2-[5-(4-METHYLPIPERAZINYL)BENZO[D]IMIDAZOL-2-YL]ACETATE
• CAS NO: 402948-37-2
• Molecular Formula: C₁₆H₂₂N₄O₂
• Molecular Weight: 302.37
• Product Categories: API intermediates
• Mol File: 402948-37-2.mol

Chemical Properties

• Boiling Point: 516.4±50.0 °C(Predicted)
• Appearance: /
• Density: 1.220±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.47±0.10(Predicted)
• CAS DataBase Reference: Ethyl 2-[5-(4-methylpiperazinyl)benzimidazol-2-yl]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-[5-(4-methylpiperazinyl)benzimidazol-2-yl]acetate(402948-37-2)
• EPA Substance Registry System: Ethyl 2-[5-(4-methylpiperazinyl)benzimidazol-2-yl]acetate(402948-37-2)

Safety Data

• Hazardous Substances Data: 402948-37-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
Ethyl 2-[5-(4-methylpiperazinyl)benzimidazol-2-yl]acetate is used as a potential pharmaceutical agent for its complex structure and the presence of various chemically-interacting rings. Its specific properties, such as melting point, boiling point, and toxicity, are crucial for determining its suitability in this application and must be established through experimental testing.
Used in Chemical Research:
Ethyl 2-[5-(4-methylpiperazinyl)benzimidazol-2-yl]acetate is used as a subject of investigation in the field of chemistry due to its unique structure and the potential for various chemical interactions. Researchers are interested in exploring its properties and possible applications, which may include the development of new drugs or other chemical products.

Upstream product

• 2318-25-4 ethyl 3-ethoxy-3-iminopropanoate hydrochloride 
• 54998-08-2 4-(4-methylpiperazino)-1,2-diaminobenzene 
• 1635-61-6 5-chloro-2-nitroaniline 
• 27317-59-5 Ethyl 3-ethoxy-3-iminopropionate 
• 23491-48-7 5-(4-methylpiperazine-1-yl)-2-nitroaniline 
• 109-01-3 1-methyl-piperazine 

Downstream Products

• 405169-16-6 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one 
• 2056122-65-5 7-amino-6-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)thieno[3,2-b]pyridin-5(4H)-one 
• 2056123-45-4 4-hydroxy-7-(4-methoxybenzyl)-5-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7H)-one 
• 405169-16-6 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 
• 692737-80-7 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one DL-lactic acid salt 

Relevant articles and documents

HPK1 inhibitor and application thereof

The invention belongs to the technical field of medicines, and specifically relates to an HPK1 inhibitor compound as shown in a formula (I) which is described in the specification or a pharmaceutically-acceptable salt and a stereoisomer of the HPK1 inhibi

Method for preparing dovitinib intermediate with microchannel reaction device

The invention discloses a method for preparing a dovitinib intermediate with a microchannel reaction device. The method comprises the following steps: (1) dissolving hydrochloric acid in ethanol to form a mixed solution, and enabling the mixed solution an

TREATMENT OF MELANOMA

Methods of treating melanoma include administering a compound of Structure (I), a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The comp

Formulation of Quinolinones

A pharmaceutical formulation, comprising: a compound of formula (I), a tautomer of the compound, a salt of the compound, a salt of the tautomer, or a mixture thereof and at least one ingredient selected from the group consisting of (i) cellulose; (ii) sil

METHODS FOR TREATING DRUG RESISTANT CANCER

A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comp

The chemical development of CHIR-258

This paper is a case history of the early stage chemical development of CHIR-258 (4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- 2(1H)-quinolinone, DL-lactate salt), a vascular endothelial growth factor (VEGF) kinase inhibitor for t

TREATMENT OF METASTASIZED TUMORS

Methods of treating metastatic cancer such as metastasized tumors include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mix

METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS

A method for synthesizing a heterocyclic compound includes: reacting 1-methylpiperazine with 5-chloro-2-nitroaniline at an internal temperature sufficient to provide a compound of Formula VIH The 1-methylpiperazine and the 5-chloro-2-nitroaniline are reac

CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALTS

The present invention relates to non-hydrate crystalline forms of 4-amino- 5-fluoro-3 -[6-(4-methylpiperazin- 1 -yl)- 1 H-benzimidazol-2-yl] - 1 H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-arnino-5-fiuoro-3-[6-(4- methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention further relates to crystalline solvates of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts.

MODULATION OF INFLAMMATORY AND METASTATIC PROCESSES

Methods of using compounds having Structure (I) or the salts or tautomers of the compounds in the treatment of disorders relating to cell adhesion and metastatic processes are presented herein.